Get started
Galectin Therapeutics Inc.Galectin Therapeutics Inc.Galectin Therapeutics Inc.

Galectin Therapeutics Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

GALT trade ideas

Can GALT Vault Back Above The 200?Looks like GALT is back hanging out around the 786 level again. This is where it was trading around before the last big spike. But there's also another level to keep track of which is the 200DMA. Now that GALT is below this level, the 200 might be another possible area of resistance. Given the post-market action on Friday (7/30), GALT managed to break above the 200 ($2.82) briefly before sliding back down to that same level by the close of the aftermarket session. Aside from technicals, there are also some fundamental things to note about GALT and you can Read More On GALT stock: 8 ‘Must Watch’ Penny Stocks For Your July 2021 List
NASDAQ:GALT
by PennyStocks101
Bullish Reversal after Options Expiration Today for GALTGALT reported positive results for cancer immunotherapy one week ago. This was followed by algorithm trading taking the stock price lower. There is high open interest on $3, $4, and $5 calls expiring today. The price should reverse and move higher with the expiration of these calls, since the options traders accomplished what they were after to keep below the strike price and will now cover their short positions. TipRanks data on 488,633 investor portfolios show that 8.4% more portfolios hold GALT in the last 7 days, so there is growth in the investor base. The temporary dip is from the options traders. (See my previous Idea for summary notes on the due diligence setup.)
NASDAQ:GALTLong
by LGALS3
Bullish ReversalBullish reversal indicators. Increasing volume with solid support, as GALT enters 2021 catalysts. NASDAQ:GALT Due Diligence Cliff's Notes: — Leading inhibitor under development for Galectin-3, key native immune system protein involved in numerous inflammatory and fibrotic diseases and various cancers. — The only drug that has ever shown any clinically meaningful (not just lab biomarker) benefit for NASH (prevention of varices), testing to repeat these results in the NASH-RX trial. — Appears to reduce the side effects of cancer immunotherapy in the MRK Keytruda combo trial. Next readout in Q2. — Upcoming hepatic impairment (HI) biomarker results will guide the potential launch to additional indications. — Chairman and largest shareholder is the multi-billionaire founder/owner of ULINE. It’s his passion. His long time exec is now the GALT CEO and he has a board member from his family wealth office. — GALT CEO is taking 80% of his pay in the form of stock. — HC Wainwright $12 price target. — Multiple shots on goal include multiple indications + combo therapy possibility for each indication (drug has excellent safety profile). — BMY stated in a patent filed last year that the Gal3 inhibitor is proven to work for cancer immunotherapy. So we know that BMY is knowledgeable/ has their eyes on this. — Finished converting all preferred shares to common shares last year (historically, this is typically done for buy-in or buyout scenarios).
NASDAQ:GALTLong
by LGALS3
Galectin Therapeutics a buy on break above 200MAVery bullish action in the stock which has been stalled by the 200MA acting as strong resistance. A break above could see a nice bull run to FIB Resistance @ $5. Indicator bullish. Average analysts price target $11 Average analysts recommendation BUY Short interest 8.47% Company profile Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA
NASDAQ:GALT
by RedHotStocks